Provided by Tiger Trade Technology Pte. Ltd.

Novo-Nordisk A/S

45.33
-0.2800-0.61%
Post-market: 45.330.00000.00%19:59 EDT
Volume:7.61M
Turnover:344.95M
Market Cap:200.50B
PE:11.32
High:45.61
Open:45.28
Low:44.95
Close:45.61
52wk High:64.16
52wk Low:35.12
Shares:4.42B
Float Shares:3.19B
Volume Ratio:0.68
T/O Rate:0.24%
Dividend:1.72
Dividend Rate:3.80%
EPS(TTM):4.00
EPS(LYR):3.62
ROE:59.82%
ROA:18.73%
PB:6.16
PE(LYR):12.52

Loading ...

European Equities Traded in the US as American Depositary Receipts Edge Lower Thursday

MT Newswires Live
·
Jul 16

United Laboratories Unit Receives $13.5 Million Milestone Payment From Novo Nordisk

MT Newswires Live
·
Jul 16

United Laboratories Secures Novo Nordisk Milestone for Obesity Drug UBT251

TIPRANKS
·
Jul 16

Moderately bullish activity in Novo Nordisk with shares up 2.46%

TIPRANKS
·
Jul 16

Sector Update: Healthcare

MT Newswires Live
·
Jul 16

Novo Nordisk Expands Cardiometabolic Reach With New Heart Failure–Obesity Trial

TIPRANKS
·
Jul 16

Novo Nordisk A/S Stock Rises Wednesday, Outperforms Market

Dow Jones
·
Jul 16

Novo Nordisk announces European Commission approval of Wegovy pill

TIPRANKS
·
Jul 16

European Equities Traded in the US as American Depositary Receipts Advance Wednesday

MT Newswires Live
·
Jul 15

Novo Nordisk Rises as Oral Wegovy Captures 89% of US Oral Weight-Loss Prescriptions vs Eli Lilly

Market Focus
·
Jul 15

This Wall Street 'theme-o-meter' Has a Clear Message: the Artificial-intelligence Bull Market is Back

Dow Jones
·
Jul 15

Novo Nordisk Takes Early Lead in Oral Weight-Loss Drug Market, Eli Lilly Aims to Catch Up

Deep News
·
Jul 15

In the Weight-loss Wars, Novo's Obesity Pill is Pulling Way Ahead of Lilly's

Dow Jones
·
Jul 15

Novo Nordisk’s New Diabetes Bet: What the UBT251 Trial Could Mean for NVO Investors

TIPRANKS
·
Jul 15

Novo Nordisk Ramps Up Share Buybacks Under DKK 15 Billion Programme

TIPRANKS
·
Jul 14

Novo Nordisk A/S Stock Rises Monday, Outperforms Market

Dow Jones
·
Jul 14

Novo Nordisk announces new data from phase 3 FRONTIER4 study of denecimig

TIPRANKS
·
Jul 12

Novo Nordisk’s Hemophilia Drug Delivers Strong Results, but Analysts See 10% Downside for NVO Stock

TIPRANKS
·
Jul 12

Novo Nordisk A/S Stock Rises Friday, Outperforms Market

Dow Jones
·
Jul 11

Novo Nordisk Halts Device Study for CagriSema: What It Means for NVO Investors

TIPRANKS
·
Jul 10